UK Vol.173 (pharmaceutical corporations: Seqirus) / Australia Vol.30

cf. Pennsylvania Vol.11 (corporations: CSL Behring) / Australia Vol.29

Our Story | CSL

Fluad In-Season | Seqirus US
Seqirus Begins Shipping 2020/21 Influenza Vaccines to U.S. Market (07/30/2020) |
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age. | @nlm_news
Seqirus Announces U.S. FDA Approval of Its First-Ever Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine (02/03/2020) | @YahooFinance
First Adjuvanted Quadrivalent Influenza Vaccine by Seqirus Receives EU Approval (08/06/2020) | CISION
Seqirus announces Health Canada approval of first cell-based seasonal influenza vaccine (12/11/2019) | CISION
Seqirus Ships Northern Hemisphere Flu Vaccines (07/15/2019) | precision vaccinations
Human Vaccines Project and Seqirus partner to advance universal flu vaccine research (28/06/2018) | @EurekAlert
Joint media release from Invest Liverpool, the Mayor of Liverpool and Seqirus (25/02/2017) | Seqirus
CSL completes purchase of Novartis’ flu vaccine business (08/03/2015) | @FiercePharma